Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17315815 | 0.88 | KDM4E (0.38) | KDM4EMAPTPOLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL17315802 | 0.86 | S1PR1 (0.41) | KDM4EMAPTHTTL3MBTL1ALDH1A1 | |
| SCHEMBL17315810 | 0.86 | L3MBTL1 (0.46) | KDM4EAGBL2POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL17622561 | 0.86 | KDM4E (0.39) | KDM4EPOLBL3MBTL1SMN1; SMN2JMJD6 | |
| SCHEMBL161012 | 0.80 | MAPT (0.40) | KDM4EAGBL2MAPTHTTPOLB | |
| SCHEMBL20406660 | 0.78 | CYP3A4 (0.40) | KDM4EAGBL2MAPTPOLBL3MBTL1 | |
| SCHEMBL21032477 | 0.77 | MAPK1 (0.41) | KDM4EPOLBL3MBTL1SMN1; SMN2MAPK1 | |
| SCHEMBL14932583 | 0.75 | L3MBTL1 (0.41) | KDM4EMAPTHTTL3MBTL1SMN1; SMN2 | |
| SCHEMBL15999650 | 0.75 | L3MBTL1 (0.41) | KDM4EMAPTHTTPOLBL3MBTL1 | |
| SCHEMBL161047 | 0.75 | MAPT (0.42) | MAPTHTTPOLBL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152213-B1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS CAYMAN LTD (KY) | 2018-10-31 | — | — | EP | disclosed |
| US-10030026-B2 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-07-24 | — | — | US | disclosed |
| US-10030026-B2 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-07-24 | — | — | US | disclosed |
| US-10030026-B2 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-07-24 | — | — | US | disclosed |
| US-20170101412-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-04-13 | — | — | US | disclosed |
| US-20170101412-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-04-13 | — | — | US | disclosed |
| US-20170101412-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-04-13 | — | — | US | disclosed |
| EP-3152213-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | Rugen Holdings (Cayman) Limited (KY) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015187845-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015187845-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10030026-B2 | Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists | GRIN1, GRIN2A, GRIN2B | KDM4E 1429/4885AGBL2 4420/4885MAPT 2386/4885 |
| US-20170101412-A1 | DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | KDM4E 1429/4885AGBL2 4420/4885MAPT 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.